SCHEMBL205715

SCHEMBL205715

COC(=O)c1ccc(/C=C/[N+](=O)[O-])cc1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.73
FBP1 P09467 8/20 0.65
ALDH1A1 P00352 3/20 0.56
VCP P55072 3/20 0.54
SYK P43405 2/20 0.54
PTPN1 P18031 1/20 0.54
ABL1 P00519 2/20 0.53
ABL2 P42684 2/20 0.53
LMNA P02545 3/20 0.51
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
GALR2 O43603 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ERBB2 P04626 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205716 1.00 EGFR (0.73) EGFRFBP1ALDH1A1VCPSYK
SCHEMBL6691537 0.94 ALDH1A1 (0.68) EGFRFBP1ALDH1A1VCPSYK
SCHEMBL6691534 0.94 ALDH1A1 (0.68) EGFRFBP1ALDH1A1VCPSYK
SCHEMBL3012399 0.83 EGFR (0.58) EGFRFBP1ALDH1A1VCPSYK
SCHEMBL3012401 0.83 EGFR (0.58) EGFRFBP1ALDH1A1VCPSYK
SCHEMBL28197210 0.83 FBP1 (0.60) EGFRFBP1ALDH1A1VCPSYK
SCHEMBL14659792 0.82 POLB (0.68) EGFRALDH1A1PTPN1MAPTMAPK1
SCHEMBL12973292 0.82 POLB (0.68) EGFRALDH1A1PTPN1MAPTMAPK1
SCHEMBL71402 0.82 PTPN1 (0.73) ALDH1A1PTPN1LMNAMAPTNPC1
SCHEMBL71401 0.82 PTPN1 (0.73) ALDH1A1PTPN1LMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111217707-B Preparation method of beta-trans-nitroolefin 西北师范大学 2022-09-16 CN disclosed
CN-111217707-A preparation method of β -trans-nitroolefin 西北师范大学 2020-06-02 CN disclosed
US-8088760-B2 Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) BIOMARIN PHARMACEUTICAL INC. (US) 2012-01-03 US disclosed
EP-2247600-A2 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) Lead Therapeutics, Inc. (US) 2010-11-10 EP disclosed
WO-2009099736-A2 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) LEAD THERAPEUTICS, INC. (US) 2009-08-13 WO disclosed
US-20090197863-A1 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) LEAD THERAPEUTICS, INC. (US) 2009-08-06 US disclosed
US-7084154-B2 2-(aminomethyl) arylamide analgesics PHARMACOPEIA DRUG DISCLOVERY, INC. (US) 2006-08-01 US disclosed
US-20040167119-A1 2-(aminomethyl) arylamide analgesics PHARMACOPEIA, INC (US) 2004-08-26 US disclosed
WO-2004071445-A2 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-08-26 WO disclosed
EP-1105396-A1 PROCESS FOR THE PREPARATION OF PYRROLO[2,3-D]PYRIMIDINES The Trustees of Princeton University (US) 2001-06-13 EP disclosed
US-6066732-A Process for the preparation of pyrrolo[2,3-d]pyrimidines THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2000-05-23 US disclosed
WO-2000011004-A1 PROCESS FOR THE PREPARATION OF PYRROLO[2,3-D]PYRIMIDINES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2000-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197863-A1 BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) PARP1, PARP2, PARP11 EGFR 3806/4885FBP1 542/4885ALDH1A1 398/4885
US-20040167119-A1 2-(aminomethyl) arylamide analgesics OPRL1, OPRM1, OPRK1 EGFR 3970/4885FBP1 3072/4885ALDH1A1 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.